Patents Examined by Pancham Bakshi
  • Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
    Patent number: 11697693
    Abstract: Large molecular weight alginates which are covalently modified to store and release nitric oxide, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both planktonic and biofilm-based bacteria.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: July 11, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Mona Jasmine R. Ahonen, Dakota J. Suchyta, Kaitlyn Rose Rouillard
  • Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
    Patent number: 11685710
    Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: June 27, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Daniel J. Siegwart, Jason B. Miller
  • Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
    Patent number: 11680053
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: June 20, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Aves, Benjamin Gerald Tehan
  • Method for producing silicone-based adhesive
    Patent number: 11680194
    Abstract: A method for producing a silicone-based adhesive is disclosed. The method comprises: (1) applying a silicone composition (I) to one surface of a peelable substrate, and then forming a silicone layer (I) by curing or drying the silicone composition (I); and (2) applying a silicone composition (II) to a surface of the silicone layer (I), and then forming the silicone-based adhesive by curing the silicone composition (II). The silicone composition (I) contains a silicone resin. The silicone composition (II) either does not contain the silicone resin or if contained, its content amount is lower than that in the silicone composition (I). The method is useful for producing a silicone-based adhesive with low peel resistance from a peelable substrate even with a low modulus.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 20, 2023
    Assignee: DOW TORAY CO., LTD.
    Inventors: Takakazu Hino, Michitaka Suto, Akihiro Nakamura
  • Cancer treatment
    Patent number: 11667718
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: June 6, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
    Patent number: 11667910
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: June 6, 2023
    Assignee: CureVac Manufacturing GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Pivarubicin and benzarubicin compositions
    Patent number: 11666589
    Abstract: The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: June 6, 2023
    Inventors: Leonard Lothstein, Judith Soberman, Tiffany N. Seagroves
  • N-3 immunoresolvents: structures and actions
    Patent number: 11667598
    Abstract: The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 6, 2023
    Assignee: The Brigham & Women's Hospital Inc.
    Inventors: Charles N. Serhan, Jesmond Dalli
  • Carbohydrate conjugates as delivery agents for oligonucleotides
    Patent number: 11666653
    Abstract: The present invention provides a modified RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand targets an HBV mRNA; all of the nucleotide sugars of the RNAi agent are 2?-modified; and at least one of the sense and antisense strands is conjugated to at least one targeting ligand that comprises two or more building blocks connected to a biantennary or triantennary branched linker, optionally via one or more linking groups.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: June 6, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Martin Maier
  • Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
    Patent number: 11666592
    Abstract: The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: June 6, 2023
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Michio Hirano, Caterina Garone, Ramon Marti
  • Low dose combination CDA substrate drug/cedazuridine with extended administration
    Patent number: 11660310
    Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: May 30, 2023
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
  • Treatment of Rett syndrome
    Patent number: 11660306
    Abstract: The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: May 30, 2023
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Nicholas Tonks, Navasona Krishnan
  • Prodrug-type anticancer agent using cancer-specific enzymatic activity
    Patent number: 11655269
    Abstract: To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: May 23, 2023
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Yasuteru Urano, Mako Kamiya, Kento Hayashi
  • Complexes
    Patent number: 11649258
    Abstract: The present invention provides a palladium(II) complex of formula (1). R12, m, and X are described in the specification. The invention also provides a process for the preparation of the complex, and its use in carbon-carbon and carbon-heteroatom coupling reactions.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: May 16, 2023
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Thomas Colacot, Ruishan Chow, Andrew Jon DeAngelis
  • Purification method of high-purity n-tetrasilane
    Patent number: 11649168
    Abstract: A high-purity n-tetrasilane purification method includes: introducing a tetrasilane (Si4H10) isomeric mixture into a solidifying purification tank, cooling the tetrasilane (Si4H10) to a predetermined temperature with refrigerant in the solidifying purification tank, maintaining the predetermined temperature between the freezing temperature of the n-tetrasilane (n-Si4H10) and of the i-tetrasilane (i-Si4H10), solidifying the n-tetrasilane (n-Si4H10) in the tetrasilane (Si4H10) isomeric mixture into solid state, and vacuuming the i-tetrasilane (i-Si4H10) from the mixture for separation.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 16, 2023
    Assignee: Taiwan Speciality Chemicals Corporation
    Inventors: Sung-Yueh Shieh, Teng-Chih Lee
  • Chiral control
    Patent number: 11643657
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: May 9, 2023
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
    Patent number: 11633411
    Abstract: The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R1 and R2 may be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, R3 may be OH or a mono-, di- or poly-saccharide, R4, R5, R6 and R7 may be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R8, R9, R10 and R11 may be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: April 25, 2023
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Robert K. Ernst, Erin M. Harberts, Alison J. Scott
  • Water-soluble, high-molecular-weight chitosan powders
    Patent number: 11634561
    Abstract: The poor water solubility of high molecular weight chitosan has limited its use in areas such as food and beverage products, post-harvest treatments, cosmetic and pharmaceutical products, medical treatments, and environmental pollution treatments. Disclosed is a high-molecular-weight, solid-state chitosan powder that is completely water-soluble.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: April 25, 2023
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Witoon Prinyawiwatkul, Zhimin Xu, Yixiao Shen
  • RUNX2 transcription factor inhibitors and uses thereof
    Patent number: 11634381
    Abstract: Provide herein are compounds with a general chemical structure of: Substituents R1 and R2 independently are H, Cl, F, Br, CH3, CF3, SH, —N(C1-3alkyl)2, —NHC(O)C1-3alkyl, or —NHC(O)C5-7cycloalkyl, substituent R3 is H or C1-3 alkyl and R4 is a bridged cycloalkene such as a bridged cyclohexene or a bridge-substituted cyclohexene. The compounds are therapeutics to treat a cancer, such as breast cancer, or metastatic cancers, to inhibit RUNX2 activity, such as protein expression, in a cancer cell and to increase survival of a subject with breast cancer.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: April 25, 2023
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Antonino Passaniti, Alexander D. MacKerell, Jr.
  • Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis-benzylthio-octanoic acid
    Patent number: 11622950
    Abstract: The invention provides methods, compositions, and medical kits for treating pancreatic cancer using (i) 6,8-bis(benzylsulfanyl)octanoic acid or a pharmaceutically acceptable salt thereof in combination with (ii) gemcitabine or a pharmaceutically acceptable salt thereof, and (iii) nab-paclitaxel.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: April 11, 2023
    Assignee: Cornerstone Pharmaceuticals, Inc.
    Inventors: Sanjeev Luther, Robert G. L. Shorr